Holen Sie sich die Stockscreener-App
211.85
0.41%
-0.88
Handel nachbörslich:
212.64
0.79
+0.37%
Schlusskurs vom Vortag:
$212.73
Offen:
$209.465
24-Stunden-Volumen:
1.46M
Relative Volume:
1.02
Marktkapitalisierung:
$30.34B
Einnahmen:
$2.50B
Nettoeinkommen (Verlust:
$-226.32M
KGV:
-129.08
EPS:
-1.6412
Netto-Cashflow:
$71.51M
1W Leistung:
+4.30%
1M Leistung:
+2.20%
6M Leistung:
-11.07%
1J Leistung:
+32.28%
1-Tages-Spanne:
$204.16
$213.26
1-Wochen-Bereich:
$200.17
$225.70
52-Wochen-Spanne:
$131.81
$256.36
Natera Inc Stock (NTRA) Company Profile
Firmenname
Natera Inc
Sektor
Branche
Telefon
650-249-9090
Adresse
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
211.85 | 30.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
473.95 | 179.15B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
178.08 | 124.65B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
560.73 | 43.45B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
137.40 | 38.14B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
379.77 | 36.52B | 3.77B | 449.25M | 240.68M | 7.8556 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | William Blair | Outperform |
| 2026-01-07 | Eingeleitet | Citigroup | Buy |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-10-27 | Hochstufung | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-08 | Fortgesetzt | Craig Hallum | Buy |
| 2024-02-20 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-11-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Eingeleitet | Stephens | Overweight |
| 2022-03-08 | Eingeleitet | Goldman | Buy |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-09-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-09-17 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-05-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Eingeleitet | JP Morgan | Neutral |
| 2018-07-05 | Bestätigt | Piper Jaffray | Overweight |
| 2017-08-07 | Bestätigt | Morgan Stanley | Overweight |
| 2016-11-10 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-23 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-11 | Bestätigt | The Benchmark Company | Buy |
| 2016-04-19 | Eingeleitet | The Benchmark Company | Buy |
| 2015-09-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2015-08-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2015-07-27 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-07-27 | Eingeleitet | Wedbush | Neutral |
Alle ansehen
Natera Inc Aktie (NTRA) Neueste Nachrichten
Natera(NTRA.US) Director Sells US$17.18 Million in Common Stock - Moomoo
Director Roelof Botha-linked vehicles sell 78K Natera (NTRA) shares - Stock Titan
IVF Patients Say Natera Profited Off Ineffective Embryo Tests - Law360
Natera Adds Oncology Veterans Thomas Lynch and Eric Rubin to Board - citybiz
Natera adds two oncology experts to board of directors By Investing.com - Investing.com Australia
Natera adds two oncology experts to board of directors - Investing.com
Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors - Yahoo Finance
Did Supreme Court’s Refusal to Hear Natera Appeal Just Shift CareDx’s (CDNA) Investment Narrative? - simplywall.st
Natera expands Austin operations with new sequencing facility - MSN
NTRA & Diakonos partner to use Signatera in refractory melanoma trial - MSN
NTRA Assumed by Wolfe Research -- Rating Upgraded to Outperform - GuruFocus
Wolfe Research initiates Natera stock coverage with outperform rating - Investing.com UK
Natera Inc stock (US6323071042): Wolfe Research initiation and recent price action in focus - AD HOC NEWS
Wolfe Research initiates Natera stock coverage with outperform rating By Investing.com - Investing.com South Africa
[144] Natera, Inc. SEC Filing - Stock Titan
NTRA (NASDAQ: NTRA) insider sells multiple lots, files to resell 3,000 shares - Stock Titan
U.S. Supreme Court rejects CareDx appeal in Natera false-advertising dispute - Reuters
U.S. Supreme Court rejects Natera, CareDx false-advertising dispute - TradingView
NTRA & Diakonos Partner to Use Signatera in Refractory Melanoma Trial - Yahoo Finance Singapore
Natera And 2 Other Companies That May Be Trading Below Their Estimated Value - Yahoo Finance
Natera, Inc. (NTRA) Stock Analysis: Impressive Revenue Growth Amidst a Challenging Valuation Landscape - DirectorsTalk Interviews
Natera to launch enhanced Panorama NIPT for low fetal fractions - MSN
Is Natera (NTRA) Quietly Redefining Its Moat With MRD Trials And Sequencing Scale-Up? - Yahoo Finance
Natera’s Solomon Moshkevich on how MRD testing pinpoints cancer recurrence - MedTech Dive
High Growth Tech Stocks in US for May 2026 - simplywall.st
Natera (NTRA) Partners with Diakonos Oncology for Melanoma Trial - GuruFocus
Natera, Diakonos Oncology Pair to Test Molecular Response in Refractory Melanoma Patients - Contract Pharma
Why Natera Is My Favorite Stock Idea for the Rest of 2026 - Yahoo Finance
Natera partners with Diakonos for melanoma therapy trial By Investing.com - Investing.com South Africa
Natera partners with Diakonos for melanoma therapy trial - Investing.com UK
Natera's Signatera Selected by Diakonos Oncology for Use in Melanoma Trial - Moomoo
Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma - Yahoo Finance
NTRA Stock Price, Quote & Chart | NATERA INC (NASDAQ:NTRA) - ChartMill
Natera president John Fesko sells $291,683 in shares By Investing.com - Investing.com India
Natera president sells $335,091 in company stock By Investing.com - Investing.com India
Natera president sells $335,091 in company stock - Investing.com UK
Natera president John Fesko sells $291,683 in shares - Investing.com
Natera (NTRA) president sells 1,652 shares to cover RSU tax obligations - Stock Titan
Natera (NTRA) president sells 1,438 shares to cover RSU tax withholding - Stock Titan
Natera to Launch Enhanced Panorama NIPT for Low Fetal Fractions - The Globe and Mail
Natera Clinical Milestones Raise Questions On Growth Versus Valuation Risk - Sahm
Citi Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $300 - Moomoo
How Investors May Respond To Natera (NTRA) Boosting Panorama NIPT And Scaling Sequencing Capacity - simplywall.st
Natera (NTRA) Initiates Patient Enrollment for Early-Stage Breas - GuruFocus
Natera’s SIGNAL-ER 101 Study Assesses MRD Testing for ER+ Breast Cancer Treatment Decisions - geneonline.com
Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer - The Malone Telegram
Finanzdaten der Natera Inc-Aktie (NTRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.78%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):